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The CST complex (CTC1-STN1-TEN1) has been shown to inhibit telomerase extension of the G-
strand of telomeres and facilitate the switch to C-strand synthesis by DNA polymerase alpha-
primase (pol α-primase). Recently the structure of human CST was solved by cryo-EM, allowing 
the design of mutant proteins defective in telomeric ssDNA binding and prompting the 
reexamination of CST inhibition of telomerase. The previous proposal that human CST inhibits 
telomerase by sequestration of the DNA primer was tested with a series of DNA-binding 
mutants of CST and modeled by a competitive binding simulation. The DNA-binding mutants 
had substantially reduced ability to inhibit telomerase, as predicted from their reduced affinity 
for telomeric DNA. These results provide strong support for the previous primer sequestration 
model. We then tested whether addition of CST to an ongoing processive telomerase reaction 
would terminate DNA extension. Pulse-chase telomerase reactions with addition of either wild-
type CST or DNA-binding mutants showed that CST has no detectable ability to terminate 
ongoing telomerase extension in vitro. The same lack of inhibition was observed with or 
without pol α-primase bound to CST. These results suggest how the switch from telomerase 
extension to C-strand synthesis may occur. 
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Telomerase, a ribonucleoprotein enzyme, comprises a template-containing RNA (1), a reverse 
transcriptase protein (2), and accessory subunits that differ among ciliates, vertebrates, and 
yeast (3,4). By maintaining chromosomal telomere length, telomerase allows continuous 
proliferation of stem cells and cancer cells. The last decades have witnessed substantial 
progress in understanding telomerase’s enzymatic mechanism, biogenesis, recruitment to 
telomeres, and three-dimensional structure (5-8). At the same time, research has begun to 
shed light on the synthesis of the C-rich strand of the telomere (9-14). 
 
Key to the switch from telomeric G-strand synthesis by telomerase to C-strand synthesis by pol 
α-primase is the CST complex, consisting of CTC1, STN1, and TEN1 (15,16). CST binds single-
stranded DNA (ssDNA) with some specificity for the telomeric sequence (15, 17,18). CST 
prevents telomerase re-initiation by sequestering the 3’ end of the telomeric primer (17). It also 
directly binds pol α-primase and acts as a cofactor for stimulation of pol α-primase activity (19). 
Structures of various domains and subcomplexes of CST were solved by X-ray crystallography in 
the Skordalakes lab (20,21). The cryo-EM structure then showed how these domains were 
incorporated into the heterotrimer and revealed a binding site for single-stranded telomeric 
DNA in the CTC1 subunit (22). Unexpectedly, these heterotrimers can also self-assemble into a 
2 megadalton decameric supercomplex with an overall double-ring structure (22). Although 
data support the existence of the decamer in cells, it remains challenging to ascertain which 
functions (or additional functions) of CST are accomplished by the heterotrimer versus the 
decamer (22). 
In this work, we utilize human CST DNA-binding mutant proteins that maintain assembly of the 
heterotrimeric complex but have reduced affinity for telomeric DNA. We find that these mutant 
proteins have reduced ability to inhibit initiation of telomerase extension. Quantitative profiles 
of telomerase inhibition as a function of added CST were well fit by an exact treatment of 
competitive primer binding using experimentally validated binding constants. This analysis 
provides strong support for the primer sequestration model of Chen, Redon and Lingner (17). 
We then tested whether CST could terminate ongoing extension of telomeric DNA by 
telomerase, which would provide a powerful mechanism to switch from G-strand synthesis to 
C-strand synthesis. However, we show that such termination does not occur to an appreciable 
extent under multiple conditions in vitro. Together, our data support the model where CST 
primarily blocks telomerase through primer sequestration, with the switch from telomerase G-
strand synthesis to pol α-primase C-strand synthesis occurring either passively or facilitated by 
factors beyond the telomerase holoenzyme, the CST complex, and pol α-primase.   
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MATERIALS AND METHODS 
 
Reagents 
Other than stated, we purchased chemicals from Sigma-Aldrich (St. Louis, MO) or Thermo 
Fisher Scientific (Waltham, MA), DNA modifying enzymes from New England Biolabs (NEB, 
Ipswich, MA) and DNA oligonucleotides from Integrated DNA Technologies (IDT, Coralville, IA). 
The 18-nucleotide 3xTEL DNA is 5I-TTAGGGTTAGGGTTAGGG-3I. For fluorescence polarization 
binding assays, 3xTEL was 5I 6-carboxyfluorescein labeled by IDT. 
 
Biological resources 
The pcDNA mammalian expression vector (V79020, Thermo Fisher Scientific) was used to clone 
cDNAs expressing the human CST subunits. The CTC1 cDNA (MGC: 133331) has a 3xFLAG tag, 
STN1 cDNA (MGC: 2472) a Myc tag, and TEN1 cDNA (MGC: 54300) a HA tag, all three tags 
residing on the N-termini of the proteins. CTC1 mutagenesis was performed using standard 
DNA mutagenesis protocol and confirmed by sequencing the gene. HEK239T cells (CRL-1573, 
ATCC, Manassas, VA) were cultured in DMEM medium supplemented with 2 mM L-glutamine, 
1% penicillin/streptomycin, and 10% fetal bovine serum.  
 
Expression and purification of proteins in human cultured cells  
The three plasmids encoding the CST subunits were transfected into HEK293T cells at 1:1:1 
molar ratio using lipofectamine 2000 (11668019, Thermo Fisher Scientific). The cells were 
further expanded (typically three-fold) for 24 h after transfection and then harvested. The cell 
pellets were lysed with CHAPS lysis buffer (10 mM Tris-HCl pH 7.5, 1 mM MgCl2, 1 mM EGTA, 
0.5% CHAPS, 10% glycerol, 5 mM β-mercaptoethanol, 1 mM PMSF) for 45 min at 4 °C on a 
rotator. The lysate was then clarified by centrifugation at 13,000 x g at 4 °C for 30 min. Anti-
FLAG resin (A2220, Sigma-Aldrich) was added to the clarified supernatant and the samples 
incubated in a rotator for 4 h (or overnight) at 4 °C. The anti-FLAG resins were washed thrice 
with wash buffer (20 mM HEPES-NaOH pH 8.0, 150 mM NaCl, 2 mM MgCl2, 0.2 mM EGTA, 0.1% 
NP-40, 10 % glycerol, 1 mM TCEP) before elution using wash buffer supplemented with 0.25 
mg/mL 3xFLAG peptide (F4799, Sigma-Aldrich). The eluent was then subjected to another 
round of affinity purification using anti-HA resin (26181, Thermo Fisher Scientific) with similar 
buffers but 3xFLAG peptide replaced with HA peptide (A6004, APExBIO, Houston, TX) for 
elution. Purified CST complexes were verified with SDS-PAGE using a silver staining kit (24612, 
Thermo Fisher Scientific). For experiments that required pol α-primase removal from CST, the 
NaCl concentration in the wash and elution buffers was raised from 150 mM to 300 mM.  
 
CST protein concentrations were determined by western blot analysis with anti-CTC1 antibody 
(see next section) using a serial dilution of the HEK-cell CST preparation and a standard curve 
obtained by serial dilution of an insect cell-purified CST standard. The same quantification with 
anti-STN1 antibody consistently gave a 3-fold lower protein concentration, possibly because of 
different post-translational modifications in the HEK cell and insect cell preparations; if the 
STN1-derived protein concentrations had been used, the Kd and IC50 values reported herein 
would all be 3-fold lower (i.e., tighter binding), but the relative Kd values would be unchanged. 
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The presence of CST and pol α-primase subunits in the HEK239T cell-purified CST complexes 
was analyzed by western blotting. The primary antibodies were anti-FLAG (A8592, Sigma-
Aldrich), anti-HA (NB600-362H, Novus Biologicals, Centennial, CO), anti-CTC1 (MABE 1103, EMD 
Millipore, Burlington, MA), anti-STN1 (NBP2-01006, Novus Biologicals, Centennial, CO), anti-
POLA1 (ab31777, Abcam, Cambridge, UK), anti-POLA2 (21778-1-AP, ProteinTech, Rosemont, IL), 
anti-PRIM1 (10773-1-AP, ProteinTech), and anti-PRIM2 (NBP2-58498, Novus Biologicals). 
Secondary antibodies used were anti-rabbit (711-035-152, Jackson ImmunoResearch, West 
Grove, PA) and anti-mouse (715-035-150, Jackson ImmunoResearch). All primary antibodies 
were diluted 1:1,000 for blotting. The dilution for secondary antibodies was performed 
according to the manufacturer’s recommendations. 
 
Electrophoresis mobility shift assay (EMSA)    
The 3xTEL oligo was 5I radiolabeled with [γ-32P]ATP (NEG035C005MC, PerkinElmer) using a 
standard T4 polynucleotide kinase labeling protocol (M0201L, NEB). Each binding reaction (10 
μL sample volume) contained 500 counts per min (c.p.m.) of radiolabeled 3xTEL in binding 
buffer (20 mM HEPES-NaOH pH 8.0, 150 mM NaCl, 2 mM MgCl2, 0.2 mM EGTA, 0.1 % NP-40, 
10% glycerol, 1 mM DTT) with or without CST added. The binding reactions were incubated on 
ice for 2h before loading onto a 1X TBE, 0.7 % SeaKem® LE Agarose (50004, Lonza Group, Basel, 
Switzerland) agarose gel. Gel electrophoresis was performed in a cold room (4 °C) for 1.5 h at 
6.6 volts/cm. The gels were dried on Hybond N+ (RPN303B, Cytiva Amersham™, Little Chalfont, 
UK) and 2 pieces of 3MM chromatography paper (3030917, Cytiva Whatman™) at 80°C for 1.25 
h.  They were then exposed to a phosphorimager screen overnight. The screen was imaged with 
a Typhoon FLA9500 scanner (GE Lifesciences). The fraction of the DNA bound   was calculated 
by dividing the counts from the gel-shifted band(s) over total counts per lane. The apparent 
dissociation constant, Kd,app., was then determined from fitting the fraction bound values to the 
following Hill equation, 
        ,.         (1) 
 
Where P is the CST protein concentration and n is the Hill coefficient. 
 
Fluorescent polarization (FP) binding assay 
Each binding reaction (20 μL sample volume) contained 750 pM of fluorescently labeled 3xTEL 
oligo in either EMSA binding buffer (for telomerase) or telomerase binding buffer (for CST). 
Serial dilutions of binding reactions were set up in a 384-well plate (Cat No: 3575, Corning Inc., 
Corning, NY). Control wells with only binding buffer were also included in each experiment. The 
binding reactions were incubated for 1.5-2 h at room temperature in the dark. Fluorescent 
intensity (parallel and perpendicular polarization) of each reaction were measured using a 
ClarioStar Plus FP plate reader (BMG Labtech, Ortenberg, Germany) and fluorescent anisotropy 
values of each protein titration were calculated. Kd,app. was determined by fitting the anisotropy 
value (FA) to the quadratic equation for single site binding by non-linear least squares fitting, 
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Where O is the minimum anisotropy observed, S is the difference between the maximum and 
minimum anisotropy observed, P is the concentration of protein, and [L] is the concentration of 
DNA. Averages calculated are the mean values from experiments. 
 
Direct telomerase assay 
Human telomerase expression and purification followed the protocol of Cristofari and Lingner 
(23). The telomerase extension assay was performed in 50ImM Tris-HCl pH 8.0, 50ImM KCl, 
75ImM NaCl (some brought in with CST and the remainder supplemented), 2ImM MgCl2, 
1ImM spermidine, 5ImM β-mercaptoethanol, 0.33IμM [α-32P]dGTP (3000ICi mmol−1), 
2.9IμM cold dGTP, 0.5ImM dATP, and 0.5ImM TTP.  
 
For standard experiments, CST, telomerase (2.0 nM), and 3xTEL oligo (10 nM unless indicated 
otherwise) were incubated at room temperature for 30 min before 3Iμl of dNTP mix was added 
to initiate telomerase extension (final reaction volume of 20Iμl). The samples were incubated 
at 30I°C for 1Ih (unless indicated otherwise) before adding 100 μl of stop solution (3.6IM 
NH4Ac containing 20Iμg glycogen and 3000Ic.p.m. of each of three oligonucleotide loading 
controls, LC1, LC2, and LC3). The samples were ethanol precipitated and then dissolved in 10 μl 
water plus 10 μl 2x gel loading buffer (0.1× TBE, 93% formamide, 50ImM EDTA, 0.05% 
bromophenol blue, and 0.05% xylene cyanol). 10Iμl of each sample was loaded on a 10% 
acrylamide, 7IM TBE-urea sequencing gel (pre-run for 45 min at 90 W constant) and 
electrophoresis was performed at 90 W constant until the bromophenol blue dye was at the 
bottom of the gel, about 2 h. The gel was then dried and exposed to a storage phosphor screen 
before imaging. 
 
For experiments in which CST was added to an ongoing telomerase reaction, telomerase and 
3xTEL oligo were preincubated at room temperature for 30 min before initiating telomerase 
extension (by adding dNTP mix). CST proteins were then added to the reaction 2 or 10 min after 
dNTP addition. For pulse-chase experiments, excess cold dGTP and CST were added to the 
telomerase reactions immediately after the 10 min time point. Radiolabeled telomerase DNA 
synthesis products were analyzed by ImageQuant (GE Lifesciences). Telomerase activity was 
determined by total counts per lane, and processive extension was calculated as counts in high 
molecular weight products (≥ 10 repeats) divided by total counts per lane.  IC50 values were 
determined by fitting the telomerase activity data to the equation 





    (3) 
 
Where P is the CST protein concentration. 
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Competitive binding modeling and simulation 
The following exact mathematical equations for calculating fraction of ligand bound to protein,  , in a competitive binding situation (originally derived by Wang (24) were coded into a python 
script, 





     (4) 








    (5) 
   


        (6) 




    !
  !
      (8) 
 
The script was designed to accept user input parameters; 
 and 
, the dissociation 
constants of the competing binders (Telomerase and CST, respectively) for the ligand (DNA); 
, the concentration of ligand; 
, the concentration of Telomerase; and 
, a titrated 
range of initial concentrations of CST.  
 
The final expression calculated is  
	
	
,  or fraction of telomerase bound to DNA ligand. 
Normalized fraction bound was then calculated by dividing all values by the value of fraction 
bound evaluated at 
 = 0 nM (in the absence of CST). The equation was also adapted from the 
original version to accept a manipulatable, unitless γ factor that represented the percent of 
active CST. This factor was added as a coefficient to concentration of protein B (CST) before 
calculating normalized fraction bound of ligand to telomerase. 
 
Fitting of experimental telomerase inhibition data 
Best fit curves were generated for experimental competitive binding data. An array of 100 γ 
values ranging linearly from 0.0 to 2.0 and an array of 100 
 values ranging linearly from 0.0 
to 4.0 were created. For every pair of γ and 
  values, a python script was used to calculate 
the Residual Sum of Squares (RSS) between the exact equation’s predicted fraction bound and 
the experimentally determined fraction bound under the same conditions according to the 
following equation, 
 '((",   ∑ #  * +#!$#%$        (9) 
 
Where #  is the experimentally determined fraction bound, * +#! is the exact equation’s 
prediction of fraction bound under #’s conditions, and  is the total number of experimental 
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data points. The value of 
 was set at 2.20 nM, the concentration of telomerase at 2.0 nM, 
and DNA concentrations ranged between 5.0 nM, 10.0 nM, 25.0 nM, 50.0 nM, 100.0 nM, and 
200.0 nM, corresponding to telomerase-CST inhibition experiments. 10,000 RSS values were 
calculated with a minimum value of 0.499 and maximum value of 28.1. Error space was 
visualized with a 2D heat map corresponding to RSS values for each γ, 
  pair. The darkest 
color was set to correspond to the minimum RSS value and the brightest color was set to twice 
of the saturation RSS value.  
 
The pair with the lowest RSS was then used to generate best fit curves and plotted with 








CST mutant proteins defective in binding ssDNA 
 
The cryo-EM structure of human CST revealed a binding site for four nucleotides (TAGG) of the 
TTAGGG telomeric repeat in Oligonucleotide/oligosaccharide Binding Folds (OB folds) F and G 
of the CTC1 subunit (22). Mutagenesis was performed on groups of amino acids (designated 
“g”), designed to give a substantial reduction in DNA affinity (Figure 1A). A negative control 
mutant g4.1 switched the charge of two amino acids that are not directly involved in DNA 
binding. While qualitative DNA binding experiments with some of these mutants have been 
reported (22), the present studies required quantitative measurements.  
 
The three CST subunits were coexpressed in HEK-293T cells. A double affinity pull-down 
method relying on a 3xFLAG tag on CTC1 and a HA tag on TEN1 resulted in substantially pure 
CST complexes (Supplementary Figure S1). The WT and all mutant proteins all assembled stable 
heterotrimers, as judged by co-IP of the three subunits (Figure 1B). It initially appeared that the 
protein preparation contained four contaminating polypeptides (Supplementary Figure S1), but 
mass spectrometry and western blots showed that these were in fact the subunits of pol α-
primase, known binding partners of CST (26-29) (Figure 1C). Because pol α-primase was not 
overexpressed, these subunits are endogenous. 
 
The CTC1 subunit consistently ran as two bands, both containing the N-terminal 3xFLAG tag and 
the epitope for the CTC1 antibody. The upper band has a molecular weight consistent with full-
length CTC1 (135 kDa), while the lower band X (ca. 114 kDa) is of unknown origin. Interestingly, 
mutant g1.1 was bereft of pol α-primase and of the faster-migrating CTC1 species, providing a 
useful tool to test whether these components affect DNA binding. Pol α-primase binding 
appears to be required for nuclear localization of CST (29), but how this could be related to the 
absence of the smaller CST isoform is unclear. 
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DNA binding affinity was assessed by both Electrophoretic Mobility Shift Assays (EMSA) and 
Fluorescence Polarization (FP). Each technique has its advantages, the EMSA allowing detection 
of a single or multiple bound species, and the FP being more of a true equilibrium technique. 
For practical reasons, the EMSA was done at 4 °C and the FP at 22 °C, so one would not expect 
the apparent dissociation constant (Kd,app) values to be the same, but the trends seen with the 
mutants should be consistent between assays. 
 
Sample EMSA data are shown in Figure 2A. The three mutants designed to be defective in DNA 
binding bound the 3xTEL DNA probe at much higher protein concentrations than the WT or g4.1 
control mutant.  Furthermore, the DNA binding-defective mutants all showed at least two DNA-
bound complexes on the native agarose gel. The species with the greater retardation had an 
electrophoretic mobility similar to that of the bound species seen with WT CST and the g4.1 
mutant, while the new species ran at an intermediate mobility. It seems unlikely that the 
intermediate species contains a subcomplex rather than a complete CST heterotrimer, because 
the three subunits remained associated during immunopurification (Figure 1B) and 
subcomplexes do not have such high EMSA mobility (30) or structural stability (30,31). In any 
case, the DNA-binding mutants displayed a 30-50 fold reduction in affinity to the 3xTEL ssDNA, 
while the negative control had a Kd,app similar to that of WT CST (Figure 2B and Table 1). The 
curve fits gave Hill coefficients of 1.02 , 0.18 (n = 9 experiments) for WT CST and 1.03 , 0.19  
(n = 14 experiments) for the DNA binding mutants, indicating that binding was not cooperative. 
 
FP data are plotted in Figure 2C and compiled in Table 1. Consistent with the EMSA data, the 
DNA-binding mutants showed a large increase in Kd,app , and the g4.1 negative control had a 
Kd,app similar to that of WT CST. Interestingly, the reduction in affinity for the DNA-binding 
mutants observed in the FP assays was greater than in the EMSA experiments, 190-360 fold for 
FP compared to 15-32 fold for EMSA (Table 1). The differences could be explained by the 
inherent differences of the two assays, with the FP assays being performed at a higher 
temperature as mentioned above and the FP assays being run at a lower salt concentration to 
match the telomerase inhibition experiments. Furthermore, the FP assay is better suited than 
EMSA for measuring binding with weaker binding proteins due to it being a true equilibrium 
experiment. Overall, though, the trends between the two experiments are consistent. 
 
CST inhibition of telomerase initiation depends on DNA binding 
 
To compare the ability of various CST complexes to inhibit the initiation of telomerase 
extension, direct telomerase assays were performed. When telomerase was incubated with the 
3xTEL telomeric DNA primer and dNTPs, the 6-nt ladder of extension products characteristic of 
telomerase was observed, and incorporation of radioactive [α-32P]dGTP nucleotides was linear 
for at least two hours (Figure 3A,B). When WT CST was preincubated for 30 min with 
telomerase and the primer, the pattern of extension products was unchanged but the intensity 
of the bands decreased (Figure 3C). The decrease depended on the concentration of CST, with 
an IC50 = 62 , 5 nM (range of two experiments, 10 nM DNA primer) (Figure 3D). As expected, 
the IC50 increased with increasing DNA primer concentration (Figure 3E, Supplementary Figure 
S2).   
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When the g1.1, g2.1, and g3.1 DNA-binding mutants of CST were added to the telomerase 
reaction, the inhibition required much higher CST concentrations (Supplementary Figure S3). In 
more extensive studies of the g2.1 and g3.1 mutants, weak inhibition was observed at low 
primer concentrations (IC50 ~1000 nM), but with 100 nM primer, no inhibition was observed 
even at 1000 nM CST (Supplementary Figures S4 and S5). Thus, inhibition of the initiation of 
telomerase activity by CST is dependent on CST’s DNA-binding activity. The negative control 
g4.1 mutant showed robust inhibition, with an IC50 = 10 nM at 10 nM DNA primer and IC50 = 471 
nM at 100 nM DNA primer (Supplementary Figure S6), similar to WT CST. 
 
Because these inhibition reactions involve two tight-binding entities (telomerase and CST) 
competing for binding to the DNA primer, it is not immediately apparent how IC50 relates to Kd. 
Thus, in the next section we utilize mathematical modeling to simulate the inhibition curves and 
fit them to our experimental data. 
 
Simulating telomerase inhibition by CST with the exact competitive binding expression 
 
The DNA primer sequestration model for telomerase inhibition can be considered a competitive 
binding equilibrium between CST and telomerase for the DNA primer (17). The schema in Figure 
4A illustrates how this competition is governed by dissociation constants defined independently 
for CST and telomerase based on the free and bound concentrations of all species.   
 
The concentrations of DNA, CST, and telomerase relative to the magnitudes of Kds of CST and 
telomerase for DNA in our telomerase activity assay were such that the common simplifying 
assumptions to the competitive binding scenario were not applicable. We thus used the exact, 
assumption-free mathematical expression for competitive binding situations derived by Wang 
(24). This exact expression was coded into a python script to accept a series of manipulatable 
parameters: dissociation constants for two competing binders (
 and 
), concentration of 
ligand, initial concentration of constant binder A (telomerase), and a range of initial 
concentrations of titrated protein B (CST). The script calculated normalized fraction bound of 
telomerase to ligand at each input concentration of titrated CST (see Materials and Methods). 
The fraction bound values were then plotted against CST concentration on a logarithmic scale.  
 
A series of test simulations were performed to verify that this exact expression behaved as 
expected (Supplementary Figure S7). With five different ligand concentrations (5, 25, 50, 100 
and 200 nM) and a 2 nM concentration of telomerase (conditions of the telomerase activity 
assay), we simulated the behavior of the exact expression at several ratios of dissociation 
constant of CST (
) to dissociation constant of telomerase (
). The concentration of 
titrated CST ranged from 0 to 1,000 nM.  As expected, the higher the ratio of CST-DNA 
 to 
telomerase-DNA 
 (the weaker CST’s affinity for DNA relative to telomerase’s affinity for 
DNA), the more the normalized fraction bound telomerase curves shifted to the right (more CST 
was required to sequester DNA from telomerase).  This is apparent in Supplementary Figure S7 
by comparing the family of curves in each panel.  
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Also as expected, increasing the initial concentration of DNA shifted the fraction bound curve to 
the right regardless of the ratio of CST-DNA 
to telomerase-DNA 
  (compare the different 
curves within each panel in Supplementary Figure S7). With more DNA in solution, more CST 
was necessary to bind all available DNA, thereby sequestering it from telomerase. These 
simulations confirmed that exact expression behaved as expected. We then proceeded to fit 
the expression to the telomerase inhibition data to determine if the inhibition of telomerase 
action by CST could be successfully modelled as a competitive binding situation.   
 
Fitting experimental telomerase inhibition data to the exact competitive binding expression 
 
The exact competitive binding expression was then used to fit the telomerase inhibition data 
collected at a range of DNA concentrations to determine if the primer sequestration model 
accurately described telomerase inhibition by CST. Several input conditions for the expression 
were known in the telomerase inhibition activity assays or determined experimentally through 
independent methods, including initial DNA concentration, telomerase concentration, titrated 
CST concentrations, and CST-DNA 
 (determined to be 2.2 ± 0.28 nM via FP, Figure 2C). This 
left two unknown variables to be fit using our model, the telomerase-DNA 
 and the active 
concentration of CST. For the percent of active CST, we modified the exact expression derived 
by Wang (24) to include a manipulatable, unitless gamma factor as a coefficient on the 
concentration of CST that represented the percent of active CST. 
 
To simultaneously fit all the experimental data, we tested a set of 10,000 Telomerase-DNA KDBs 
and gamma pairs (with limits set by reasonable physical approximations) to find the pair that 
minimized error between fraction bound values predicted by the exact expression and values 
determined in the telomerase inhibition assays. The error between predicted and experimental 
fraction bound was quantified by calculating the Residual Sum of Squares (RSS) for each 
gamma, 
 pair (see Materials and Methods). 
 
Using this strategy, optimized values were found to be a 
 of 0.324 nM and a gamma of 
0.465. The optimized fit 
 for telomerase-DNA binding was similar to that of 0.54 + 0.25 nM 
independently determined for our telomerase enzyme by FP (Table 1 and Supplementary Figure 
S8). These values were then used to generate the best fit curves plotted with telomerase 
inhibition data (Figure 4B). Note that even at the lowest [DNA] = 5 nM, the calculated IC50 is ~70 
nM CST, far greater than the binding constant 
 = 2.2 nM. The high IC50 concentration 
matches both experimental and fit telomerase 
 values, which show telomerase has roughly 
a 4-7 fold higher affinity to DNA than CST. 
 
While a 
 of 0.324 nM and a gamma of 0.465 resulted in lowest error, other pairs had 
similarly low error values: the RSS values for each pair are represented in a heat map (Figure 
4C). This spread of low error values indicated that there is a range of pairs that similarly fit the 
inhibition data well. These fits show that our data convincingly support competitive primer 
binding as a model for telomerase-CST inhibition. 
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CST does not inhibit ongoing extension of telomeric DNA by telomerase 
 
As shown above, CST can compete with telomerase for binding the DNA primer and thereby 
inhibit initiation of G-strand synthesis. A much more powerful mode of CST inhibition might 
occur if it could attack and disrupt ongoing telomerase extension. However, our data suggested 
that CST might not affect ongoing extension. First, when WT CST was added to the telomerase 
reaction at 2 min or at 10 min, the incorporation of radioactivity into telomerase reaction 
products was largely but not entirely curtailed (Figure 5A,B). Second, existing extension 
products continued to elongate (Figure 5C). Both observations were consistent with CST 
inhibiting initiation of new telomerase reactions but not affecting ongoing extension. 
 
The ladder of extension products in telomerase reactions is generally thought to result from 
processive extension, because the excess of unextended primer in the reactions should act as 
an internal “chase” and prevent rebinding of telomerase to previously extended products 
(32,33). To test if the long extension products that continued to accumulate after CST addition 
were in fact due to processive elongation of previously initiated chains, we performed pulse-
chase experiments. Instead of chasing with a 3’-end-blocked DNA primer, which would prevent 
telomerase reinitiation but would also bind to CST, we added an excess of unlabeled dGTP 
along with the CST immediately after the 10 min timepoint so that all further nucleotide 
incorporation would be unlabeled. An example of such an experiment is shown in Figure 5D. 
Three observations confirmed that the pulse-chase experiment was working as expected. First, 
incorporation of radiolabel stopped immediately upon the addition of cold dGTP, present in 
3000x excess over the radiolabeled dGTP (Figure 5E). Second, smaller extension products at 10 
min decreased in intensity at subsequent time points, as they were chased into longer 
extension products (see, for example, 7, 8 and 9 repeats). Third, longer products continued to 
accumulate after 10 min. (As expected, the high [dGTP] stimulated telomerase processivity (34-
36).)  In conclusion, the addition of a saturating amount of WT CST clearly does not inhibit 
ongoing processive telomerase activity. 
 
To control for possible nonspecific effects of adding protein to the reaction, WT CST was 
compared side-by-side with the g2.1 DNA-binding mutant. As shown in Figure 5F,G,H, the WT 
and g2.1 mutant additions gave essentially identical results. Neither of them inhibited further 
extension of previously initiated primers (Figure 5H). The stuttering banding pattern (synthesis 
stalls at 3 nt as well as 6 nt in each repeat) is caused by the higher ratio of dGTP:Mg
++
 in this 
experiment (5 mM dGTP:1 mM MgCl2). Thus, even under conditions where telomerase 
extension is suboptimal, the CST has no detectable ability to inhibit ongoing telomerase 
extension. Pulse-chase reactions with 1 mM dGTP:1 mM MgCl2, which do not give the 
stuttering pattern, again showed no difference between WT and g2.1 CST (Figure 6C). 
 
CST inhibits telomerase extension independent of bound pol α-primase 
 
Pol α-primase copurified with the CST purified from HEK-293T cells. The exception was the g1.1 
mutant, which lost pol α-primase association (Figure 1C, Supplementary Figure S1). Because the 
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g1.1 mutant inhibited telomerase activity only at high concentrations, similar to g2.1 and g3.1 
which retain pol α-primase, it appeared that pol α-primase was not responsible for the 
inhibition seen with CST. 
 
We sought an independent test of this hypothesis. We found that immunopurification of the 
CST under higher salt conditions, 300 mM KCl instead of our standard 150 mM KCl, released the 
pol α-primase without otherwise affecting the purification of CST (Figure 6A). The 150 mM and 
300 mM KCl preparations of CST were compared in a pulse-chase experiment, and they were 
found to be equivalent: they both prevented further initiation of telomerase, and they both 
allowed processive extension of pre-initiated chains (Figure 6B-E). Thus, pol α-primase does not 




The switch from telomeric G-strand synthesis by telomerase to C-strand synthesis by pol α-
primase is a critical step in telomere replication. The CST complex is key in orchestrating this 
switch, but its mechanism of action is incompletely known. Here we extend the understanding 
of CST inhibition of telomerase extension in three ways. First, we validate DNA-binding mutants 
of CST and show that they no longer inhibit telomerase initiation, providing strong additional 
support for the primer sequestration model. Second, we develop an exact model for CST 
inhibition of telomerase, which reconciles the Kd values for telomerase and CST binding to the 
DNA primer with the much higher IC50 values obtained from the inhibition curves. Finally, we 
show that CST does not have the intrinsic ability to evict telomerase from telomeric DNA during 
a primer-extension reaction.  
 
An exact model for CST inhibition of telomerase 
 
While CST has previously been suggested to inhibit telomerase through the direct and 
competitive binding of the telomeric ssDNA ligand, more sophisticated actions by CST could not 
be ruled out (17). We have determined the extent to which a competitive binding model 
evaluated with an exact treatment of coupled equilibrium (24) fits the experimental telomerase 
inhibition profiles. The strength of this approach is that it requires no a priori assumptions 
about relative dissociation constants or limiting values to predict the equilibrium 
concentrations of all species. This model, however, treats the telomerase-DNA interaction as a 
straightforward binding interaction, a potentially deleterious oversimplification of the complex 
enzymatic machinery. Phenomenon such as partial dissociations, multiple binding modes, 
processivity and change in affinity for an active telomerase are not expected to be accurately 
encapsulated by a single binding constant. Thus, it is somewhat surprising that this model 
represents the inhibition data quite well. Furthermore, the fitted value for telomerase-DNA 
binding affinity (Figure 4B) matches within error to the value obtained independently in a 
binding experiment (Table 1). This binding affinity (0.52 ± 0.25 nM) is similar to other values 
reported in the literature measured with alternate methods of 0.5 ± 0.3 nM (37) and 3.3 ± 0.5 
nM (38). The high congruence of the model with the data, as well as the consistent telomerase-
DNA affinity values obtained, strongly support that the core action of telomerase inhibition by 
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CST is through the mechanism of competitive binding for ligand. This mechanism suggests the 
possibility that regulation of telomerase action could be achieved by controlling the CST 
concentration at the telomere. 
 
How does CST terminate telomerase extension? 
 
Telomerase is unable to extend ssDNA primers in the presence of a saturating amount of CST. 
This activity can be explained by a simple primer sequestration model (17). That is, CST binding 
to the primer sequesters it and precludes telomerase binding. Our detailed quantitative 
analysis with DNA-binding mutants of CST provides strong confirmation of the primer 
sequestration model with no need to invoke additional CST activities.  
 
How effective might CST inhibition of initiation be for termination of telomerase in vivo? During 
homeostatic telomere length maintenance, human telomerase is thought to extend most 
telomeres in each cell cycle, adding about 60 nt to each telomere processively after a single 
binding event (39). The intrinsic activities of CST determined by in vitro analysis are in complete 
accord with such a model. Given its ability to sequester the primer and block reinitiation, CST 
could help restrict telomerase extension to a single round. Because it is unable to evict 
telomerase from elongating DNA, it would not interfere with the single round of extension.  
 
On the other hand, when telomeres are undergoing net elongation, Zhao et al. (39) report that 
multiple telomerase molecules act at each telomere; i.e., extension is distributive rather than 
processive. Perhaps under these conditions there is insufficient CST available at the telomere to 
prevent telomerase reinitiation. 
 
How does the switch from telomerase synthesis of the telomeric G-strand to pol α-primase 
synthesis of the C-strand occur? Because we find no evidence that CST can evict telomerase 
from elongating DNA under multiple in vitro conditions, the switch from G-strand to C-strand 
synthesis may be passive rather than active. Given its modest processivity, telomerase will 
terminate spontaneously after adding a limited number of telomeric repeats, measured as ~4 
repeats in vitro (40) and ~10 repeats in cells (39).  Inhibition occurs when CST then binds the 
newly extended DNA and prevents telomerase reinitiation. At the same time, CST brings in pol 
α-primase to initiate C-strand synthesis.  
 
The relative activity of the CST heterotrimeric “monomer” and the 2-megadalton decameric 
supercomplex in inhibiting telomerase is not addressed by our study. We think that the results 
presented here pertain to the CST monomer. The HEK cell-based CST purification gives low 
concentrations of CST, and under these conditions we have not observed the decameric 
supercomplex (although our evidence suggests that it is present in cells (22)). Given that the 
decamer is poised to bind ssDNA more aggressively than the monomer (22), we might expect it 
to have greater telomerase-inhibiting activity than the monomer. 
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The experimental approaches and computational analysis developed herein provide the 
groundwork for future studies to test the activity of additional telomere components, such as 
the shelterin complex, on the switch from telomeric G-strand to C-strand synthesis. 
AVAILABILITY 
CST_Inhibits_Telomerase is available in the GitHub repository 
(https://github.com/mtcarilli/CST_Inhibits_Telomerase). 
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TABLE AND FIGURE LEGENDS 
 
Table 1. Equilibrium dissociation constants for binding of CST and telomerase to 3xTEL DNA by 
EMSA at 4°C and by FP at room temperature. Each value is the mean , SD of n independent 
experiments. Relative Kd values are normalized to WT CST. For the weak-binding CST mutants, 
the FP binding curves did not go to completion, so the Kd values are approximate.  
 
Figure 1. CST DNA-binding mutants maintain subunit assembly and mostly maintain pol α-
primase binding. (A) Location of mutated amino acids relative to the DNA (half opaque surface 
representation, orange) in the cryo-EM structure of CST (22). Grey ribbon, CTC1. Dark surface, 
STN1. (B) All mutants maintain assembly of CTC1, STN1 and TEN1 subunits. Insect cell 
recombinant CST (shown here on WT CST gel) was always included to allow plotting a standard 
curve to calculate concentration of HEK cell CST. Lack of reliable anti-TEN1 antibody led us to 
probe the HA-tagged TEN1 with anti-HA antibody; the insect cell TEN1 lacked this tag, so was 
not revealed. The lower band of CTC1, of unknown origin, was consistently missing in the g1.1 
mutant. (C) WT CST and all mutants except g1.1 co-purify with pol α-primase, shown here for 
the two pol α subunits and in Supplementary Figure S1 for the primase subunits. In panels (B) 
and (C), wedges indicate successive two-fold dilutions of protein. 
 
Figure 2. CST mutants show large loss of affinity for telomeric ssDNA. (A) Representative EMSA 
gels of 3xTEL DNA binding by WT and mutant CST proteins. (B) Quantification of fraction of DNA 
bound with error bars representing SD from multiple experiments (see Table 1).            
(C) Representative binding curves from FP assays of 3xTEL binding by WT and mutant CST 
proteins. Equations 1 and 2 were used for curve fitting.  
 
Figure 3. CST inhibits telomerase initiation. (A) Direct assay with telomerase immunopurified 
from HeLa cells, unlabeled 10 nM 3xTEL DNA primer, and nucleotides including [
32
P]dGTP. LC1, 
LC2 and LC3 are oligonucleotides added as loading controls. (B) Radioactivity incorporated into 
telomerase products as a function of reaction time. (C) Telomerase assay for 1 h with the DNA 
primer pre-incubated with WT CST at the concentrations shown. (D) Counts incorporated into 
telomerase products normalized to the counts incorporated in the absence of CST. Data from 
two technical replicates included and fit to equation 3. (E) Dependence of IC50 on the 
concentration of 3xTEL DNA in the reaction. Parentheses on last data point indicate that it is 
underdetermined, because only partial inhibition was achieved at the highest CST 
concentration. 
 
Figure 4. Fitting telomerase inhibition data. (A) Schema of competitive binding mechanism and 
relevant equilibrium equations. (B) Best fit telomerase inhibition curves. Telomerase inhibition 
assay data (points) plotted with predicted fraction bound curves for experimental DNA 
concentrations generated with optimized Kd,A and γ values of 0.324 nM and 0.465, respectively. 
Inhibition by WT CST. (C) Heat map of error values. Error values (Residual Sum of Squares, see 
Methods) as a function of γ and Kd Telomerase-DNA pairs with pair of best fit indicated. Value 
of error colored per bar on right. 
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Figure 5. Pulse-chase experiments show that CST does not disrupt ongoing telomerase 
extension. (A) Direct telomerase assay with WT CST added after 2 or 10 min of reaction. All 
three time courses had the same [
32
P]GTP, so intensity differences are due to inhibition by 
added CST. (B) Radioactivity incorporated into telomerase products as a function of reaction 
time. (C) Long extension products (≥10 repeats, see bar to right of panel a) as a fraction of total 
incorporation. Data points are connected to aid visualization.  (D) Pulse-chase experiment in 
which excess unlabeled dGTP was added along with CST to restrict observed products to 
previously initiated chains. High [dGTP] drives high processivity. (E) Radioactivity incorporated 
into telomerase reaction products stops increasing when unlabeled dGTP is added at 10 min. 
Data points are connected to aid visualization. (F) WT CST and DNA-binding mutant g2.1 CST are 
equally unable to disrupt ongoing telomerase extension under conditions that cause 
telomerase stuttering. Pulse-chase experiments with 5 mM unlabeled dGTP instead of the 
standard 1 mM dGTP. The pre-mix control (first four lanes) shows that the addition of the 
unlabeled dGTP was sufficient to prevent further labeling of products. (G) Radioactivity 
incorporated into telomerase products in the experiment of panel (F). Symbols for WT and g2.1 
CST overlap. (H) Long extension products as a fraction of total incorporation in the experiment 
of panel (F). Data points are connected to aid visualization. The values with no CST addition are 
lower because small products continue to be initiated, increasing the total counts relative to 
the long extension products. 
 
Figure 6. CST inhibits telomerase extension independent of bound pol α-primase. (A) Western 
blot analysis of WT CST purified in standard 150 mM NaCl or in 300 mM NaCl. Top blots probed 
with antibodies to CTC1 and to the large subunit of pol α. Bottom blots probed with antibodies 
to STN1, the small subunit of pol α, and the two subunits of primase (Prim 1 and 2). Wedges 
indicate successive two-fold dilutions of protein. (B) Pulse-chase experiment with WT CST 
purified in 300 mM NaCl. (C) Pulse-chase experiments with WT CST purified in 150 mM NaCl 
(left lanes) and with g2.1 mutant CST purified in 150 mM NaCl (right lanes). (D) Radioactivity 
incorporated into telomerase products as a function of reaction time without chase (No CST) or 
in the pulse-chase experiments of panel (B) and left half of (C) (300 and 150, respectively).       
(E)  Long extension products (≥10 repeats) as a fraction of total incorporation in the same 
pulse-chase experiments. Data points are connected to aid visualization. 
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Figure 1. CST DNA-binding mutants maintain subunit assembly and mostly maintain pol α−primase
binding. (A) Location of mutated amino acids relative to the DNA (half opaque surface
representation, orange) in the cryo-EM structure of CST (22). Grey ribbon, CTC1. Dark surface,
STN1. (B) All mutants maintain assembly of CTC1, STN1 and TEN1 subunits. Insect cell
recombinant CST (shown here on WT CST gel) was always included to allow plotting a standard
curve to calculate concentration of HEK cell CST. Lack of reliable anti-TEN1 antibody led us to
probe the HA-tagged TEN1 with anti-HA antibody; the insect cell TEN1 lacked this tag, so was
not revealed. The lower band of CTC1, of unknown origin, was consistently missing in the g1.1
mutant. (C) WT CST and all mutants except g1.1 co-purify with pol α-primase, shown here for
the two pol α subunits and in Supplementary Figure S1 for the primase subunits. In panels (B)
and (C), wedges indicate successive two-fold dilutions of protein.
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Figure 2. CST mutants show large loss of affinity for telomeric ssDNA. (A) Representative EMSA
gels of 3xTEL DNA binding by WT and mutant CST proteins. (B) Quantification of fraction of DNA
bound with error bars representing SD from multiple experiments (see Table 1).
(C) Representative binding curves from FP assays of 3xTEL binding by WT and mutant CST
proteins. Equations 1 and 2 were used for curve fitting.
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Figure 3. CST inhibits telomerase initiation. (A) Direct assay with telomerase immunopurified
from HeLa cells, unlabeled 10 nM 3xTEL DNA primer, and nucleotides including [32P]dGTP. LC1,
LC2 and LC3 are oligonucleotides added as loading controls. (B) Radioactivity incorporated into
telomerase products as a function of reaction time. (C) Telomerase assay for 1 h with the DNA
primer pre-incubated with WT CST at the concentrations shown. (D) Counts incorporated into
telomerase products normalized to the counts incorporated in the absence of CST. Data from
two technical replicates included and fit to equation 3. (E) Dependence of IC50 on the
concentration of 3xTEL DNA in the reaction. Parentheses on last data point indicate that it is
underdetermined, because only partial inhibition was achieved at the highest CST
concentration.
(   )
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Figure 4. Fitting telomerase inhibition data. (A) Schema of competitive binding mechanism and relevant 
equilibrium equations. (B) Best fit telomerase inhibition curves. Telomerase inhibition assay data (points) 
plotted with predicted fraction bound curves for experimental DNA concentrations generated with optimized 
Kd,A and γ values of 0.324 nM and 0.465, respectively. Inhibition by WT CST. (C) Heat map of error values. 
Error values (Residual Sum of Squares, see Methods) as a function of γ and Kd Telomerase-DNA pairs 
with pair of best fit indicated. Value of error colored per bar on right.
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Figure 5. Pulse-chase experiments show that CST does not disrupt ongoing telomerase extension. (A) Direct telomerase assay with WT CST added
after 2 or 10 min of reaction. All three time courses had the same [32P]GTP, so intensity differences are due to inhibition by added CST. (B)
Radioactivity incorporated into telomerase products as a function of reaction time. (C) Long extension products (≥10 repeats, see bar to right of
panel A) as a fraction of total incorporation. Data points are connected to aid visualization. (D) Pulse-chase experiment in which excess unlabeled
dGTP was added along with CST to restrict observed products to previously initiated chains. High [dGTP] drives high processivity. (E) Radioactivity
incorporated into telomerase reaction products stops increasing when unlabeled dGTP is added at 10 min. Data points are connected to aid
visualization. (F) WT CST and DNA-binding mutant g2.1 CST are equally unable to disrupt ongoing telomerase extension under conditions that cause
telomerase stuttering. Pulse-chase experiments with 5 mM unlabeled dGTP instead of the standard 1 mM dGTP. The pre-mix control (first four
lanes) shows that the addition of the unlabeled dGTP was sufficient to prevent further labeling of products. (G) Radioactivity incorporated into
telomerase products in the experiment of panel (F). Symbols for WT and g2.1 CST overlap. (H) Long extension products as a fraction of total
incorporation in the experiment of panel (F). Data points are connected to aid visualization. The values with no CST addition are lower because
small products continue to be initiated, increasing the total counts relative to the long extension products.
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Figure 6. CST inhibits telomerase extension independent of bound pol α-primase. (A) Western
blot analysis of WT CST purified in standard 150 mM NaCl or in 300 mM NaCl. Top blots probed
with antibodies to CTC1 and to the large subunit of pol α. Bottom blots probed with antibodies
to STN1, the small subunit of pol α, and the two subunits of primase (Prim 1 and 2). Wedges
indicate successive two-fold dilutions of protein. (B) Pulse-chase experiment with WT CST
purified in 300 mM NaCl. (C) Pulse-chase experiments with WT CST purified in 150 mM NaCl
(left lanes) and with g2.1 mutant CST purified in 150 mM NaCl (right lanes). (D) Radioactivity
incorporated into telomerase products as a function of reaction time without chase (No CST) or
in the pulse-chase experiments of panel (B) and left half of (C) (300 and 150, respectively).
(E) Long extension products (≥10 repeats) as a fraction of total incorporation in the same
pulse-chase experiments. Data points are connected to aid visualization.
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